CoChat

Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease

Open access
Wooddell, Christine I., Blomenkamp, Keith, Peterson, Ryan M., Subbotin, Vladimir M., Schwabe, Christian, Hamilton, James, Chu, Qili, Christianson, Dawn R., Hegge, Julia O., Kolbe, John, Hamilton, Holly L., Branca-Afrazi, Maria F., Given, Bruce D., Lewis, David L., Gane, Edward, Kanner, Steven B., Teckman, Jeffrey H. · 2020 · JCI Insight
Cited by 60

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The autosomal codominant genetic disorder alpha-1 antitrypsin (AAT) deficiency (AATD) causes pulmonary and liver disease. Individuals homozygous for the mutant Z allele accumulate polymers of Z-AAT protein in hepatocytes, where AAT is primarily produced. This accumulation causes endoplasmic reticulum (ER) stress, oxidative stress, damage to mitochondria, and inflammation, leading to fibrosis, cirrhosis, and hepatocellular carcinoma. The magnitude of AAT reduction and duration of response from first-generation intravenously administered RNA interference (RNAi) therapeutic ARC-AAT and then with next-generation subcutaneously administered ARO-AAT were assessed by measuring AAT protein in serum of the PiZ transgenic mouse model and human volunteers. The impact of Z-AAT reduction by RNAi on liver disease phenotypes was evaluated in PiZ mice by measuring polymeric Z-AAT in the liver; expression of genes associated with fibrosis, autophagy, apoptosis, and redox regulation; inflammation; Z-AAT globule parameters; and tumor formation. Ultrastructure of the ER, mitochondria, and autophagosomes in hepatocytes was evaluated by electron microscopy. In mice, sustained RNAi treatment reduced hepatic Z-AAT polymer, restored ER and mitochondrial health, normalized expression of disease-associated genes, reduced inflammation, and prevented tumor formation. RNAi therapy holds promise for the treatment of patients with AATD-associated liver disease. ARO-AAT is currently in phase II/III clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.135348

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 60

Metadata

Authors
Wooddell, C. I., Blomenkamp, K., Peterson, R. M., Subbotin, V. M., Schwabe, C., Hamilton, J., Chu, Q., Christianson, D. R., Hegge, J. O., Kolbe, J., Hamilton, H. L., Branca-Afrazi, M. F., Given, B. D., Lewis, D. L., Gane, E., Kanner, S. B., & Teckman, J. H.
Venue
JCI Insight
Published
2020-06-18
Volume
5
Issue
12
ISSN
2379-3708 (ISSN-L)
OpenAlex
W3023605248
Cited by
60
References
5
FWCI
2.56
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease. https://app.cochat.ai/papers/10.1172/jci.insight.135348
The paper
Wooddell, C. I., Blomenkamp, K., Peterson, R. M., Subbotin, V. M., Schwabe, C., Hamilton, J., Chu, Q., Christianson, D. R., Hegge, J. O., Kolbe, J., Hamilton, H. L., Branca-Afrazi, M. F., Given, B. D., Lewis, D. L., Gane, E., Kanner, S. B., & Teckman, J. H. (2020). Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease. JCI Insight. https://doi.org/10.1172/jci.insight.135348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.